Cargando…

Neurobiological pathways to Alzheimer’s disease: Amyloid-beta, TAU protein or both?

Alzheimer’s disease (AD) is a neurodegenerative disease characterized by progressive cognitive decline, including memory loss, behavioral and psychological symptoms and personality changes. The neuropathological hallmarks of AD are the presence of neuritic (senile) plaques (NP) and neurofibrillary t...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Paula, Vanessa de Jesus R., Guimarães, Fabiana Meira, Diniz, Breno Satler, Forlenza, Orestes Vicente
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Associação de Neurologia Cognitiva e do Comportamento 2009
Materias:	Views & Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618972/ https://www.ncbi.nlm.nih.gov/pubmed/29213627 http://dx.doi.org/10.1590/S1980-57642009DN30300003

Ejemplares similares

Lithium and neuroprotection: translational evidence and implications for the treatment of neuropsychiatric disorders
por: Diniz, Breno Satler, et al.
Publicado: (2013)

Diagnosis and biomarkers of predementia in Alzheimer's disease
por: Forlenza, Orestes V, et al.
Publicado: (2010)

Plasma Biomarkers of Alzheimer’s Disease: A Review of Available Assays, Recent Developments, and Implications for Clinical Practice
por: Pais, Marcos V., et al.
Publicado: (2023)

Planning ability impairments in probable Alzheimer's disease patients: Evidence from the Tower of London test
por: Satler, Corina, et al.
Publicado: (2017)

Neurobiology of neuropsychiatric symptoms in Alzheimer's disease: A critical review with a focus on neuroimaging
por: Tascone, Lyssandra dos Santos, et al.
Publicado: (2013)

Neurobiology and the Humanities
por: Zeki, Semir
Publicado: (2014)

Criteria for the diagnosis of Alzheimer’s disease: Recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology
por: Frota, Norberto Anízio Ferreira, et al.
Publicado: (2011)

Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia
por: Forlenza, Orestes V., et al.
Publicado: (2015)

Amyloid-beta and phosphorylated tau in post-mortem Alzheimer’s disease retinas
por: den Haan, Jurre, et al.
Publicado: (2018)

The Role of Amyloid-Beta and Tau in the Early Pathogenesis of Alzheimer’s Disease
por: Yin, Xiaomin, et al.
Publicado: (2021)

Amyloid-beta peptide and tau protein crosstalk in Alzheimer’s disease
por: Roda, Alejandro R., et al.
Publicado: (2022)

A systematic review of the neurobiological aspects of memory in the aging process
por: de Oliveira, Eduardo Moreira, et al.
Publicado: (2011)

Detection of Alzheimer's disease amyloid beta 1‐42, p‐tau, and t‐tau assays
por: van Harten, Argonde C., et al.
Publicado: (2021)

Recent Neurobiological Insights into the Concept of Insight in Psychosis
por: Mythri, Starlin Vijay, et al.
Publicado: (2016)

Anti-amyloid agents for treating incipient Alzheimer’s disease: a new hope?
por: Loureiro, Julia C., et al.
Publicado: (2022)

Combining Cognitive Screening Tests for the Evaluation of Mild Cognitive Impairment in the Elderly
por: Ladeira, Rodolfo B., et al.
Publicado: (2009)

Could blocking the formation of amyloid channels rescue Alzheimer's phenotype?
por: Guix, Francesc X, et al.
Publicado: (2017)

Anti-amyloid-beta to tau-based immunization: developments in immunotherapy for Alzheimer’s disease
por: Lambracht-Washington, Doris, et al.
Publicado: (2013)

Blood Beta-Amyloid and Tau in Down Syndrome: A Comparison with Alzheimer’s Disease
por: Lee, Ni-Chung, et al.
Publicado: (2017)

Amyloid Beta and Phosphorylated Tau-Induced Defective Autophagy and Mitophagy in Alzheimer’s Disease
por: Reddy, P. Hemachandra, et al.
Publicado: (2019)

Whole-brain modeling of the differential influences of amyloid-beta and tau in Alzheimer’s disease
por: Patow, Gustavo, et al.
Publicado: (2023)

Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum
por: Milà‐Alomà, Marta, et al.
Publicado: (2020)

Can Anti–β-amyloid Monoclonal Antibodies Work in Autosomal Dominant Alzheimer Disease?
por: Imbimbo, Bruno P., et al.
Publicado: (2020)

‘To do or not to do’? The neurobiology of decision-making in daily life: I. Getting the basics
por: Palmini, André, et al.
Publicado: (2007)

Alzheimer Aβ peptide interactions with lipid membranes: Fibrils, oligomers and polymorphic amyloid channels
por: Tofoleanu, Florentina, et al.
Publicado: (2012)

Insulin Resistance as a Link between Amyloid-Beta and Tau Pathologies in Alzheimer’s Disease
por: Mullins, Roger J., et al.
Publicado: (2017)

Amyloid Beta and Tau as Alzheimer’s Disease Blood Biomarkers: Promise From New Technologies
por: Lue, Lih-Fen, et al.
Publicado: (2017)

JBPOS0101 regulates amyloid beta, tau, and glial cells in an Alzheimer’s disease model
por: Jeong, Jihoon, et al.
Publicado: (2020)

The Correlations Between Plasma Fibrinogen With Amyloid-Beta and Tau Levels in Patients With Alzheimer’s Disease
por: Fan, Dong-Yu, et al.
Publicado: (2021)

Plasma amyloid-beta oligomer and phosphorylated tau: diagnostic tools for progressive Alzheimer’s disease
por: An, Seong Soo A., et al.
Publicado: (2023)

Distinct Molecular Signatures of Amyloid-Beta and Tau in Alzheimer’s Disease Associated with Down Syndrome
por: Ichimata, Shojiro, et al.
Publicado: (2023)

Electrochemical Immunosensors Developed for Amyloid-Beta and Tau Proteins, Leading Biomarkers of Alzheimer’s Disease
por: Sharma, Abhinav, et al.
Publicado: (2023)

Neuronal–Glial Interaction in a Triple-Transgenic Mouse Model of Alzheimer’s Disease: Gene Ontology and Lithium Pathways
por: Rocha, Nicole Kemberly R., et al.
Publicado: (2020)

Corrigendum: Neuronal–Glial Interaction in a Triple-Transgenic Mouse Model of Alzheimer's Disease: Gene Ontology and Lithium Pathways
por: Rocha, Nicole Kemberly R., et al.
Publicado: (2021)

Intravenous Injection of PHF-Tau Proteins From Alzheimer Brain Exacerbates Neuroinflammation, Amyloid Beta, and Tau Pathologies in 5XFAD Transgenic Mice
por: Houben, Sarah, et al.
Publicado: (2020)

secHsp70 as a tool to approach amyloid-β42 and other extracellular amyloids
por: De Mena, Lorena, et al.
Publicado: (2017)

Amyloid Beta and Tau Proteins as Therapeutic Targets for Alzheimer's Disease Treatment: Rethinking the Current Strategy
por: Mondragón-Rodríguez, Siddhartha, et al.
Publicado: (2012)

Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer’s disease
por: Gangishetti, Umesh, et al.
Publicado: (2018)

Altered filamin A enables amyloid beta-induced tau hyperphosphorylation and neuroinflammation in Alzheimer’s disease
por: Burns, Lindsay H., et al.
Publicado: (2017)

New treatment strategies for Alzheimer's disease: is there a hope?
por: Aprahamian, Ivan, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_78n5kc4lvqf81r7l0uibba23p2